Full Press Release Details
Independent Study of the NanoVibronix UroShield Device Published in the Australian and New Zealand Continence Journal
Cited as Effective in Preventing CAUTIs and Blockages, Having a Major Impact on Quality of Life and Reducing Healthcare Resource Costs
N.Y., March 14, 2025 (Business Wire) - NanoVibronix, Inc. (NASDAQ: NAOV) (the "Company"), a medical technology
company specializing in non-invasive therapeutic devices, today announced that an independent health service study of its UroShield
is published in The Australian and New Zealand Continence Journal.
study highlights UroShield's effectiveness in preventing catheter-associated urinary tract infections (CAUTIs) and recommends its
adoption for appropriate patients with indwelling urinary catheters (IUCs). Researchers found that patients using UroShield experienced
an 86% reduction in UTI incidence; 70% reduction in catheter blockages; 82.8% less bladder irrigations performed and 52.3% less catheter
changes. The clinicians reported improved overall catheter comfort and a reduction in the need for catheter-related interventions.
Murphy, CEO of NanoVibronix, Inc., commented, "This study underscores the benefits of UroShield in enhancing patient care by reducing
CAUTI incidence and catheter blockages, minimizing catheter complications and improving overall comfort. Notably, researchers found that
UroShield required less nursing time, which eased workload demands and resulted in measurable cost savings for the healthcare provider."
complete article is available at https://www.publish.csiro.au/CJ/pdf/CJ24043.
Inc. (NASDAQ: NAOV) is a medical device company headquartered in Tyler, Texas, with research and development in Nesher, Israel, focused
on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology
allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption
of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the continuous assistance
of medical professionals. The Company's primary products include PainShield and UroShield , which are portable devices
suitable for administration at home or in any care setting. Additional information about NanoVibronix is available at: www.nanovibronix.com.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. These forward-looking statements include, but are not limited to: future expectations, plans and prospects for the
Company following the consummation of the acquisition and stockholder approval of the conversion of the Series X Preferred Stock. Forward-looking
statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks
and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified; consequently, actual
results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include,
without limitation, risks and uncertainties associated with: (i) market acceptance of our existing and new products or lengthy product
delays in key markets; (ii) negative or unreliable clinical trial results; (iii) inability to secure regulatory approvals for the sale
of our products; (iv) intense competition in the medical device industry from much larger, multinational companies; (v) product liability
claims; (vi) product malfunctions; (vii) our limited manufacturing capabilities and reliance on subcontractor assistance; (viii) insufficient
or inadequate reimbursements by governmental and/or other third party payers for our products; (ix) our ability to successfully obtain
and maintain intellectual property protection covering our products; (x) legislative or regulatory reform impacting the healthcare system
in the U.S. or in foreign jurisdictions; (xi) our reliance on single suppliers for certain product components, (xii) the need to raise
additional capital to meet our future business requirements and obligations, given the fact that such capital may not be available, or
may be costly, dilutive or difficult to obtain; (xiii) our conducting business in foreign jurisdictions exposing us to additional challenges,
such as foreign currency exchange rate fluctuations, logistical and communications challenges, the burden and cost of compliance with
foreign laws, and political and/or economic instabilities in specific jurisdictions; and (xiv) market and other conditions. More detailed
information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the
Company's filings with the Securities and Exchange Commission ("SEC"), including the Company's Annual Report
on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge
on the SEC's web site at: http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking
statements as a result of new information, future events, or otherwise, except as required by law.
Maas, Managing Principal, Hayden IR, LLC